银屑病患者启动不同类别生物制剂治疗后发生银屑病关节炎的风险
一项回顾性观察研究纳入622例初次使用生物制剂的斑块状银屑病患者,比较TNF、IL-17和IL-23抑制剂组新发银屑病关节炎的风险。经逆概率治疗加权后,IL-23抑制剂组较TNF抑制剂组发生银屑病关节炎的风险比为0.57(95%CI 0.34-0.96),IL-17抑制剂组为0.63(95%CI 0.38-1.05)。作者结论认为不同类别生物制剂患者发生银屑病关节炎的风险似乎略有不同。
要点
- 622例初次生物制剂治疗的银屑病患者中,60例(10%)在观察期间新发银屑病关节炎。
- TNF抑制剂组新发银屑病关节炎45例(14.2%),IL-17抑制剂组9例(5.5%),IL-23抑制剂组6例(4.3%)。
- 经IPTW调整后,IL-23抑制剂较TNF抑制剂发生银屑病关节炎的HR为0.57(95%CI 0.34-0.96),IL-17抑制剂为0.63(95%CI 0.38-1.05)。
核心结论
- 作者结论认为,接受不同类别生物制剂治疗的患者发生银屑病关节炎的风险似乎略有不同。
研究设计与样本
- 回顾性观察研究,纳入连续初次使用生物制剂的斑块状银屑病患者。
- 共622例患者,430例(62.4%)为男性,平均年龄46.9±12.9岁。
- 患者分别接受TNF抑制剂(n=317,50.9%)、IL-17抑制剂(n=164,26.4%)或IL-23抑制剂(n=141,22.7%)治疗。
- 采用逆概率治疗加权(IPTW)在多治疗背景下平衡各组治疗前协变量以调整潜在混杂因素,并使用IPTW Cox回归模型估计风险比(HR)。
主要发现
- 总随访2510人年,人均随访4.1±2.1年;TNF、IL-17和IL-23抑制剂队列随访人年分别为1569、486和455。
- 622例患者中60例(10%)在观察期间新发银屑病关节炎:TNF抑制剂组45例(14.2%),IL-17抑制剂组9例(5.5%),IL-23抑制剂组6例(4.3%)。
- 经IPTW后3个治疗队列均衡良好,与TNF抑制剂组相比,IL-17抑制剂组发生银屑病关节炎的HR为0.63(95%CI 0.38-1.05),IL-23抑制剂组为0.57(95%CI 0.34-0.96)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the risk of psoriatic arthritis (PsA) in plaque psoriasis (PsO) patients receiving different classes of biologics. METHODS: A retrospective observational study involving consecutive bionaïve PsO patients starting biologic treatment was performed. We compared the occurrence of PsA by the class of the biologic (tumour necrosis factor [TNF], interleukin [IL]-17, or IL-23 inhibitors) using inverse probability of treatment weighting (IPTW) in the setting of multiple treatments to balance pretreatment covariates across cohorts and thus adjust for potential confounders. An IPTW Cox regression model was used to estimate hazard ratios (HRs) of PsA for IL-17 and IL-23 inhibitors versus TNF inhibitors. RESULTS: In total, 622 patients, 430 (62.4%) males, mean ± SD age 46.9 ± 12.9 years, were included. They have been treated with TNF (n = 317, 50.9%), IL-17 (n = 164, 26.4%) or IL-23 inhibitors (n = 141, 22.7%) and followed for 2510 person-years (a mean of 4.1 ± 2.1 years per person). TNF, IL-17, and IL-23 inhibitor cohorts had a total of 1569, 486, and 455 person-years of follow-up. A total of 60 (10%) out of 622 patients on biologic therapy developed incident PsA during the observation period: 45 (14.2%) in the TNF, 9 (5.5%) in the IL-17, and 6 (4.3%) in the IL-23 inhibitor cohorts. After IPTW, the 3 treatment cohorts were well-balanced, and the HRs of PsA were 0.63 (95% CI, 0.38-1.05) for IL-17 and 0.57 (95% CI, 0.34-0.96) for IL-23 compared with the TNF treatment group. CONCLUSIONS: The risk of developing PsA appeared slightly different in patients receiving diverse classes of biologics.
引用
- Gisondi P, Bellinato F, Galeone C, et al. Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics. Ann Rheum Dis. 2025. PMID: 39919973. doi:10.1016/j.ard.2025.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。